New insights into the pathophysiology of the tuberous sclerosis complex: Crosstalk of mTOR- and hippo-YAP pathways in cell growth

References

• Osborne JP, Jones AC, Burley MW, Jeganathan D, Young J, O'Callaghan FJ, Sampson JR, Povey S. Non-penetrance in tuberous sclerosis. Lancet 2000; 355:1698; PMID:10905251; http://dx.doi.org/10.1016/S0140-6736(00)02247-9
   PubMed Web of Science ®Google Scholar
• Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372:657-68; PMID:18722871; http://dx.doi.org/10.1016/S0140-6736(08)61279-9
   PubMed Web of Science ®Google Scholar
• Martignoni G, Pea M, Reghellin D, Zamboni G, Bonetti F. PEComas: the past, the present and the future. Virchows Archiv: Int J Pathol 2008; 452:119-32; PMID:18080139; http://dx.doi.org/10.1007/s00428-007-0509-1
   PubMed Web of Science ®Google Scholar
• Dibble CC, Manning BD. Signal integration by mTORC1 coordinates nutrient input with biosynthetic output. Nat Cell Biol 2013; 15:555-64; PMID:23728461; http://dx.doi.org/10.1038/ncb2763
   PubMed Web of Science ®Google Scholar
• Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell 2012; 149:274-93; PMID:22500797; http://dx.doi.org/10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-41; PMID:22078875; http://dx.doi.org/10.1016/j.cell.2011.10.026
   PubMed Web of Science ®Google Scholar
• Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971; 68:820-3; PMID:5279523
   PubMed Web of Science ®Google Scholar
• Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, Belousova E, Sauter M, Nonomura N, Brakemeier S, de Vries PJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2013; 381:817-24; PMID:23312829; http://dx.doi.org/10.1016/S0140-6736(12)61767-X
   PubMed Web of Science ®Google Scholar
• Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013; 381:125-32; PMID:23158522; http://dx.doi.org/10.1016/S0140-6736(12)61134-9
   PubMed Web of Science ®Google Scholar
• Pan D. The hippo signaling pathway in development and cancer. Dev Cell 2010; 19:491-505; PMID:20951342; http://dx.doi.org/10.1016/j.devcel.2010.09.011
   PubMed Web of Science ®Google Scholar
• Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13:246-57; PMID:23467301; http://dx.doi.org/10.1038/nrc3458
   PubMed Web of Science ®Google Scholar
• Yu FX, Guan KL. The Hippo pathway: regulators and regulations. Genes Dev 2013; 27:355-71; PMID:23431053; http://dx.doi.org/10.1101/gad.210773.112
   PubMed Web of Science ®Google Scholar
• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Disc 2014; 13:63-79; PMID:24336504; http://dx.doi.org/10.1038/nrd4161
   PubMed Web of Science ®Google Scholar
• Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 2013; 154:1342-55; PMID:24012335; http://dx.doi.org/10.1016/j.cell.2013.08.025
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev 2010; 24:862-74; PMID:20439427; http://dx.doi.org/10.1101/gad.1909210
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev 2010; 24:72-85; PMID:20048001; http://dx.doi.org/10.1101/gad.1843810
   PubMed Web of Science ®Google Scholar
• Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett 2014; 588:2663-70; PMID:24747426; http://dx.doi.org/10.1016/j.febslet.2014.04.012
   PubMed Web of Science ®Google Scholar
• Zhao B, Li L, Wang L, Wang CY, Yu J, Guan KL. Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis. Genes Dev 2012; 26:54-68; PMID:22215811; http://dx.doi.org/10.1101/gad.173435.111
   PubMed Web of Science ®Google Scholar
• Barron DA, Kagey JD. The role of the Hippo pathway in human disease and tumorigenesis. Clin Trans Med 2014; 3:25; PMID:25097728; http://dx.doi.org/10.1186/2001-1326-3-25
   PubMedGoogle Scholar
• Tumaneng K, Schlegelmilch K, Russell RC, Yimlamai D, Basnet H, Mahadevan N, Fitamant J, Bardeesy N, Camargo FD, Guan KL. YAP mediates crosstalk between the Hippo and PI(3)K-TOR pathways by suppressing PTEN via miR-29. Nat Cell Biol 2012; 14:1322-9; PMID:23143395; http://dx.doi.org/10.1038/ncb2615
   PubMed Web of Science ®Google Scholar
• Chao Y, Wang Y, Liu X, Ma P, Shi Y, Gao J, Shi Q, Hu J, Yu R, Zhou X. Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway. J Neuro-Oncol 2014; 121:279-88; PMID:25373346; http://dx.doi.org/10.1007/s11060-014-1654-4
   PubMed Web of Science ®Google Scholar
• Rosner M, Hanneder M, Siegel N, Valli A, Hengstschlager M. The tuberous sclerosis gene products hamartin and tuberin are multifunctional proteins with a wide spectrum of interacting partners. Mutat Res 2008; 658:234-46; PMID:18291711; http://dx.doi.org/10.1016/j.mrrev.2008.01.001
   PubMed Web of Science ®Google Scholar
• Liang N, Zhang C, Dill P, Panasyuk G, Pion D, Koka V, Gallazzini M, Olson EN, Lam H, Henske EP, et al. Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. J Exp Med 2014; 211:2249-63; PMID:25288394; http://dx.doi.org/10.1084/jem.20140341
   PubMed Web of Science ®Google Scholar
• Kwiatkowski DJ. Animal models of lymphangioleiomyomatosis (LAM) and tuberous sclerosis complex (TSC). Lym Res Biol 2010; 8:51-7; PMID:20235887; http://dx.doi.org/10.1089/lrb.2009.0013
   PubMed Web of Science ®Google Scholar
• Zhou J, Brugarolas J, Parada LF. Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1. Hum Mol Genet 2009; 18:4428-41; PMID:19692352; http://dx.doi.org/10.1093/hmg/ddp398
   PubMed Web of Science ®Google Scholar
• Liu-Chittenden Y, Huang B, Shim JS, Chen Q, Lee SJ, Anders RA, Liu JO, Pan D. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26:1300-5; PMID:22677547; http://dx.doi.org/10.1101/gad.192856.112
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I, Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150:780-91; PMID:22863277; http://dx.doi.org/10.1016/j.cell.2012.06.037
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Gagliardini E, Donadoni C, Fassi A, Sangalli F, Lepre MS, Remuzzi G, Benigni A. Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney Int 2002; 62:885-94; PMID:12164870; http://dx.doi.org/10.1046/j.1523-1755.2002.00526.x
   PubMed Web of Science ®Google Scholar
• Siroky BJ, Yin H, Dixon BP, Reichert RJ, Hellmann AR, Ramkumar T, Tsuchihashi Z, Bunni M, Dillon J, Bell PD, et al. Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy. Am J Physiol Renal Physiol 2014; 307:F560-70; PMID:24920756; http://dx.doi.org/10.1152/ajprenal.00569.2013
   PubMed Web of Science ®Google Scholar
• Leaute-Labreze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taieb A. Propranolol for severe hemangiomas of infancy. New Engl J Med 2008; 358:2649-51; PMID:18550886; http://dx.doi.org/10.1056/NEJMc0708819
   PubMed Web of Science ®Google Scholar
• Atochina-Vasserman EN, Goncharov DA, Volgina AV, Milavec M, James ML, Krymskaya VP. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling. Am J Resp Cell Mol Biol 2013; 49:704-9; PMID:23947572; http://dx.doi.org/10.1165/rcmb.2013-0203RC
   PubMed Web of Science ®Google Scholar
• Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, et al. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM). Sci Trans Med 2012; 4:154ra34; PMID:23035046; http://dx.doi.org/10.1126/scitranslmed.3003840
   PubMed Web of Science ®Google Scholar
• Zhang W, Gao Y, Li P, Shi Z, Guo T, Li F, Han X, Feng Y, Zheng C, Wang Z, et al. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex. Cell Res 2014; 24:331-43; PMID:24458094; http://dx.doi.org/10.1038/cr.2014.10
   PubMed Web of Science ®Google Scholar
• Jiao S, Wang H, Shi Z, Dong A, Zhang W, Song X, He F, Wang Y, Zhang Z, Wang W, et al. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. Cancer Cell 2014; 25:166-80; PMID:24525233; http://dx.doi.org/10.1016/j.ccr.2014.01.010
   PubMed Web of Science ®Google Scholar